Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Driving assessment in preclinical Alzheimer’s disease: progress to date and the path forward ; volume:14 ; number:1 ; day:8 ; month:11 ; year:2022 ; pages:1-4 ; date:12.2022
Alzheimer's research & therapy ; 14, Heft 1 (8.11.2022), 1-4, 12.2022
- Urheber
-
Bayat, Sayeh
Roe, Catherine M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-022-01109-1
- URN
-
urn:nbn:de:101:1-2023012209244625232084
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bayat, Sayeh
- Roe, Catherine M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
GPS driving: a digital biomarker for preclinical Alzheimer disease
APOE effects on regional tau in preclinical Alzheimer’s disease
An olfactory ‘stress test’ may detect preclinical Alzheimer’s disease
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Preclinical Alzheimer’s dementia: a useful concept or another dead end?
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology
The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
APP mouse models for Alzheimer's disease preclinical studies
GPS driving: a digital biomarker for preclinical Alzheimer disease
APOE effects on regional tau in preclinical Alzheimer’s disease
An olfactory ‘stress test’ may detect preclinical Alzheimer’s disease
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Preclinical Alzheimer’s dementia: a useful concept or another dead end?
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology
The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
APP mouse models for Alzheimer's disease preclinical studies
GPS driving: a digital biomarker for preclinical Alzheimer disease
APOE effects on regional tau in preclinical Alzheimer’s disease
An olfactory ‘stress test’ may detect preclinical Alzheimer’s disease
Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Preclinical Alzheimer’s dementia: a useful concept or another dead end?
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology
The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease